<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02150720</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-FAT-2011-103</org_study_id>
    <secondary_id>EC11-341</secondary_id>
    <secondary_id>2011-006278-15</secondary_id>
    <secondary_id>SA/12/AYU/456</secondary_id>
    <nct_id>NCT02150720</nct_id>
  </id_info>
  <brief_title>Prevention of Postoperative Bleeding in Subcapital Femoral Fractures</brief_title>
  <acronym>TRANEXFER</acronym>
  <official_title>Prevention of Postoperative Bleeding in Femoral Fractures: a Multicenter, Randomized, Controlled, Parallel Clinical Trial to Assess the Efficacy of Tranexamic Acid and Fibrin Glue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main hypothesis of this clinical trial is that the use of intra-articular tranexamic acid
      and the fibrin glue plus usual hemostasis will reduce at least a 25% the postoperative blood
      loss with respect to usual hemostasis in patients undergoing subcapital femoral fractures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss (ml) after surgery</measure>
    <time_frame>The first postoperative 24h</time_frame>
    <description>The blood lost from the wound will be collected by a drainage system during the first 24 hours postoperatively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hidden blood loss</measure>
    <time_frame>The first postoperative five days</time_frame>
    <description>The hidden blood loss is the total blood loss calculated by the formula of Nadler minus the blood loss by drain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring blood transfusion</measure>
    <time_frame>The first postoperative ten days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Units of blood transfused</measure>
    <time_frame>The first postoperative ten days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with wound infection</measure>
    <time_frame>The first postoperative month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with wound dehiscence</measure>
    <time_frame>The first postoperative month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deep venous thrombosis</measure>
    <time_frame>The first postoperative ten days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>The first postoperative ten days</time_frame>
    <description>Time from hip surgery until hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured with the generic EQ-5D -5L</measure>
    <time_frame>Preoperatively, at 5 days postoperatively , 1-2, 6 and 12 months postoperative follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>During the 12 month of follow-up after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct cost</measure>
    <time_frame>During the first postoperative month</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Hip Fracture</condition>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic acid, 1g intra-articular before closing the surgery wound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibrin glue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual hemostasia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Electrocauterization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>1g intra-articular before closing the wound surgery</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <other_name>Amchafibrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibrin glue</intervention_name>
    <description>5mL intra-articular before closing the wound surgery</description>
    <arm_group_label>Fibrin glue</arm_group_label>
    <other_name>Evicel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrocauterization</intervention_name>
    <description>Coagulation blood from vessels by means of a electrocautery.</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_label>Fibrin glue</arm_group_label>
    <arm_group_label>Usual hemostasia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years

          -  Patients with unilateral subcapital femoral fracture

          -  Patients requiring hip replacement (total or partial)

          -  Signed informed consent from the patient or legal representative

        Exclusion Criteria:

          -  Known allergy to fibrin glue and tranexamic acid

          -  Multiple fractures

          -  Pathological fractures

          -  Contraceptives or estrogen therapy

          -  Use of blood salvage during surgery

          -  History compatible with thromboembolic disease:

               -  Cerebral vascular accident

               -  Ischemic heart disease (myocardial infarction, angina )

               -  Deep vein thrombosis

               -  Pulmonary Embolism

               -  Peripheral arterial vasculopathy

               -  Patients with thrombogenic arrhythmias

               -  Patients with cardiovascular stents

               -  Prothrombotic alterations in coagulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MJ Martínez-Zapata, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iberoamerican Cochrane Centre. Research Institut Hospital de la Santa Creu i Sant Pau. IIB Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol de Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Mútua Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Terrassa-Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.mapfre.com/fundacion/html/revistas/trauma/v25n4/docs/v25n4.pdf</url>
    <description>Publication of quality of life (subgroup of patients)</description>
  </link>
  <results_reference>
    <citation>Martínez-Zapata MJ, Jordán M, Aguilera X, Cánovas E, Urrutia G (en nombre del grupo TRANEXFER). Estudio prospectivo multicéntrico de una cohorte para evaluar la calidad de vida de pacientes intervenidos de fractura subcapital de fémur. Trauma 2014; 25 (4): 188-195.</citation>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2014</study_first_submitted>
  <study_first_submitted_qc>May 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hip fractures</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Randomized</keyword>
  <keyword>Fibrin glue</keyword>
  <keyword>Tranexamic acid</keyword>
  <keyword>Blood loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

